| (Values in U.S. Thousands) | May, 2026 | May, 2026 | May, 2026 | May, 2026 | May, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Actelion Ltd (ALIOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).